Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

crizotinib Articles

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib

14 May 2013

Synta's ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance

27 March 2013

Complete responses in Phase I trial of crizotinib in rare childhood cancer

18 May 2012

US FDA approves Pfizer lung cancer drug Xalkori and companion diagnostic from Abbott

30 August 2011

Two Pfizer cancer drug candidates, crizotinib and bosutinib, accepted for filing in Europe

18 August 2011

Pfizer files for US and Japanese approval of crizotinib for NSCLC

18 May 2011

Pfizer commences rolling FDA submission for lung cancer drug crizotinib; denies German VAT evasion

17 January 2011

AstraZeneca’s thyroid cancer drug candidate vandetanib meets Ph III goals, ASCO meeting told; Pfizer/crizotinib trial correction

8 June 2010

ASCO highlights include cancer drug news from Pfizer, Roche, Sanofi, Merck KGaA, Novartis and Eisai

7 June 2010

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS